Dr. Michael Orquiza, M.D.
Microbicides branch Sr. Medical Advisor
Michael Orquiza is an incoming Senior Medical Advisor in the Research Division. Prior to joining USAID, Dr. Orquiza was a medical protocol advisor in the Division of AIDS (DAIDS) Protection of Participants, Evaluation, and Policy (ProPEP) Branch at the National Institutes of Health, National Institute of Allergy and Infectious Diseases. There, he reviewed DAIDS-supported studies, provided consultation and expertise on complex human subjects protection (HSP) regulatory issues, informed colleagues on the effects of international data sharing/data protection regulations on DAIDS-supported studies in respective countries, and compiled branch metrics. Dr. Orquiza has a combined experience of over 10 years in clinical research and HSP.
Dr. Orquiza also has experience drafting the commercialization plan for a Phase II Grant for a novel drug, which attenuates genetic variants of hypercholesterolemia. His job was to introduce a small molecule into the market as an alternative to current treatment modalities for hypercholesterolemia. The small molecule alternative was expected to provide better compliance, cost-effectiveness, and improved safety profile (oral versus injectable) for those patients who have failed LDL management goals, and enhanced cost-effectiveness was derived from the ease of manufacturing, affordability, convenience of administration, and the small molecules could potentially offer better therapeutic options as compared to biologics. It was his job to demonstrate that our drug could potentially reduce the financial burdens of all stakeholders involved including the patients, insurance companies, etc. He holds an M.D. from the Philippines, an MBA and a MS in Health Systems Administration from Georgetown University. In his free time, Dr. Orquiza enjoys endurance cycling, marathon running, and tennis.
Dr. Orquiza also has experience drafting the commercialization plan for a Phase II Grant for a novel drug, which attenuates genetic variants of hypercholesterolemia. His job was to introduce a small molecule into the market as an alternative to current treatment modalities for hypercholesterolemia. The small molecule alternative was expected to provide better compliance, cost-effectiveness, and improved safety profile (oral versus injectable) for those patients who have failed LDL management goals, and enhanced cost-effectiveness was derived from the ease of manufacturing, affordability, convenience of administration, and the small molecules could potentially offer better therapeutic options as compared to biologics. It was his job to demonstrate that our drug could potentially reduce the financial burdens of all stakeholders involved including the patients, insurance companies, etc. He holds an M.D. from the Philippines, an MBA and a MS in Health Systems Administration from Georgetown University. In his free time, Dr. Orquiza enjoys endurance cycling, marathon running, and tennis.